Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia

Trial met its primary endpoint, with 64.3% of patients self-administering etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p... Biopharmaceuticals, Cardiology Milestone Pharmaceuticals, etripamil, calcium channel blocker, PSVT
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news